The Fight Against COVID19
23.82k followers • 14 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Curated by TREA
TREA analyzes over 100 million data points, interactions, relationships on company research and development activities, allowing investors to quickly gain insight without having to go through complex regulatory filings. Primary data sources include: FDA (Food and Drug Administration), NIH (National Institutes of Health), USPTO (US Patent and Trademark Office). The search parameters for generating this watchlist were (1) Above sector average Innovation Index score, (2) IP history at least 5 years (3) COVID19 (4) 2019-nCov (5) SARS-CoV-2 among others.
Performance
| Watchlist | Change Today | 1 Month Return | 1 Year Return | Total Return |
|---|---|---|---|---|
| The Fight Against COVID19 | +1.01% | - | - | - |
| ^GSPC | +0.49% | +1.02% | +25.99% | +5505.47% |
14 Symbols
| Symbol | Company Name | Last Price | Change | % Change | Market Time | Volume | Avg Vol (3 month) | Market Cap |
|---|---|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | 149.565 | +0.62 | +0.41% | 2:57 p.m. EDT | 3.29M | 7.61M | 359.96B |
| ABBV | AbbVie Inc. | 160.3431 | -0.11 | -0.07% | 2:56 p.m. EDT | 1.70M | 5.73M | 283.15B |
| PFE | Pfizer Inc. | 28.13 | +0.28 | +1.01% | 2:57 p.m. EDT | 25.49M | 42.62M | 159.40B |
| SNY | Sanofi | 48.7306 | +0.67 | +1.39% | 2:57 p.m. EDT | 739.58k | 2.02M | 121.79B |
| REGN | Regeneron Pharmaceuticals, Inc. | 969.15 | +13.39 | +1.40% | 2:56 p.m. EDT | 143.01k | 463.62k | 106.79B |
| GSK | GSK plc | 44.605 | +0.47 | +1.05% | 2:56 p.m. EDT | 1.47M | 3.32M | 91.14B |
| GILD | Gilead Sciences, Inc. | 64.7199 | -0.20 | -0.31% | 2:57 p.m. EDT | 2.61M | 7.20M | 80.70B |
| MRNA | Moderna, Inc. | 123.12 | +1.23 | +1.01% | 2:57 p.m. EDT | 1.42M | 3.88M | 47.18B |
| TAK | Takeda Pharmaceutical Company Limited | 13.375 | +0.31 | +2.41% | 2:57 p.m. EDT | 2.35M | 1.65M | 42.08B |
| BNTX | BioNTech SE | 92.2299 | +2.10 | +2.33% | 2:56 p.m. EDT | 411.74k | 603.19k | 22.23B |
| VIR | Vir Biotechnology, Inc. | 9.575 | +0.03 | +0.37% | 2:57 p.m. EDT | 264.09k | 1.05M | 1.30B |
| NVAX | Novavax, Inc. | 4.501 | +0.03 | +0.69% | 2:57 p.m. EDT | 2.13M | 6.86M | 631.95M |
| INO | Inovio Pharmaceuticals, Inc. | 11.06 | +0.06 | +0.55% | 2:51 p.m. EDT | 70.84k | 458.12k | 286.53M |
- Bloomberg
Moderna's Promise of mRNA Undercut by New RSV Vaccine
Moderna's second vaccine, meant to prevent a common respiratory virus, is calling into question the premise on which the company has staked its entire business. Gerry Smith reports on Bloomberg Television.
- MT Newswires
Royalty Pharma to Acquire Frexalimab Royalties, Milestones for $525 Million in Cash
Royalty Pharma to Acquire Frexalimab Royalties, Milestones for $525 Million in Cash
Pharmaceutical TechnologyTakeda tackles $900m restructuring plan after generics hurt annual profits
Workforce optimisation, R&D prioritisation and technology investments are on Takeda’s agenda.
Sign in to view your followed lists
© 2024 Yahoo. All rights reserved.